Nautilus Biotechnology (NAUT) Invested Capital (2020 - 2026)
Nautilus Biotechnology has reported Invested Capital over the past 7 years, most recently at $144.4 million for Q1 2026.
- Quarterly results put Invested Capital at $144.4 million for Q1 2026, down 25.73% from a year ago — trailing twelve months through Mar 2026 was $144.4 million (down 25.73% YoY), and the annual figure for FY2025 was $157.0 million, down 24.8%.
- Invested Capital reached $144.4 million in Q1 2026 per NAUT's latest filing, down from $157.0 million in the prior quarter.
- Across five years, Invested Capital topped out at $349.7 million in Q1 2022 and bottomed at $144.4 million in Q1 2026.
- Median Invested Capital over the past 5 years was $249.5 million (2024), compared with a mean of $248.6 million.
- The largest annual shift saw Invested Capital surged 1051.2% in 2022 before it fell 25.73% in 2026.
- Over 5 years, Invested Capital stood at $314.9 million in 2022, then decreased by 15.74% to $265.4 million in 2023, then fell by 21.34% to $208.7 million in 2024, then fell by 24.8% to $157.0 million in 2025, then dropped by 8.0% to $144.4 million in 2026.
- Business Quant data shows Invested Capital for NAUT at $144.4 million in Q1 2026, $157.0 million in Q4 2025, and $169.1 million in Q3 2025.